RNAZ Transcode Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RNAZ

Price (delayed)

$0.82

Market cap

$4.76M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$103.61

Enterprise value

$2.45M

Highlights
The EPS has soared by 93% QoQ and by 90% YoY
Transcode Therapeutics's debt has decreased by 24% from the previous quarter
Transcode Therapeutics's net income has decreased by 6% YoY but it has increased by 5% from the previous quarter
Transcode Therapeutics's equity has plunged by 63% from the previous quarter and by 49% YoY
The quick ratio has contracted by 41% from the previous quarter and by 36% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of RNAZ
Market
Shares outstanding
5.81M
Market cap
$4.76M
Enterprise value
$2.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.25
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$18.49M
EBITDA
-$17.97M
Free cash flow
-$18.11M
Per share
EPS
-$103.61
Free cash flow per share
-$101.17
Book value per share
$3.27
Revenue per share
$0
TBVPS
$28.88
Balance sheet
Total assets
$5.17M
Total liabilities
$3.53M
Debt
$450,571
Equity
$1.64M
Working capital
$964,848
Liquidity
Debt to equity
0.27
Current ratio
1.28
Quick ratio
0.79
Net debt/EBITDA
0.13
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-276.1%
Return on equity
-934.7%
Return on invested capital
N/A
Return on capital employed
-1,101.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RNAZ stock price

How has the Transcode Therapeutics stock price performed over time
Intraday
15.49%
1 week
51.85%
1 month
26.15%
1 year
-99.66%
YTD
-87.56%
QTD
20.06%

Financial performance

How have Transcode Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.42M
Net income
-$18.55M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 7% QoQ but it fell by 4.2% YoY
Transcode Therapeutics's net income has decreased by 6% YoY but it has increased by 5% from the previous quarter

Growth

What is Transcode Therapeutics's growth rate over time

Valuation

What is Transcode Therapeutics stock price valuation
P/E
N/A
P/B
0.25
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 93% QoQ and by 90% YoY
Transcode Therapeutics's equity has plunged by 63% from the previous quarter and by 49% YoY

Efficiency

How efficient is Transcode Therapeutics business performance
The company's return on assets has shrunk by 107% YoY and by 3.2% QoQ
The company's return on equity fell by 14% QoQ

Dividends

What is RNAZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNAZ.

Financial health

How did Transcode Therapeutics financials performed over time
The total assets is 46% more than the total liabilities
The total assets is down by 49% from the previous quarter and by 32% YoY
The quick ratio has contracted by 41% from the previous quarter and by 36% YoY
Transcode Therapeutics's debt is 73% less than its equity
Transcode Therapeutics's debt to equity has soared by 108% from the previous quarter
Transcode Therapeutics's equity has plunged by 63% from the previous quarter and by 49% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.